Afatinib (A) Vs Erlotinib (E) as Second-Line Treatment of Patients (PTS) with Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (LL8), a Phase Iii Global Trial | Publicación